Davidson Investment Advisors Sells 100,344 Shares of Pfizer Inc. (NYSE:PFE)

Davidson Investment Advisors lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 22.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 350,604 shares of the biopharmaceutical company's stock after selling 100,344 shares during the quarter. Davidson Investment Advisors' holdings in Pfizer were worth $9,302,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP lifted its position in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares during the period. Teachers Insurance & Annuity Association of America bought a new stake in shares of Pfizer in the 3rd quarter valued at $35,000. Joseph Group Capital Management boosted its stake in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 771 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $34,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target on the stock. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Bank of America reissued a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Finally, UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Up 1.6 %

PFE traded up $0.42 during midday trading on Friday, reaching $26.32. 54,560,140 shares of the company were exchanged, compared to its average volume of 38,524,395. The company has a market cap of $149.14 billion, a price-to-earnings ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company's fifty day moving average price is $26.30 and its 200 day moving average price is $27.42. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 earnings per share. Pfizer's revenue was up 24.7% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is presently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.